International Journal of Multidisciplinary Research in Biotechnology, Pharmacy, Dental and Medical Sciences (IJMRBPDMS)

Precision Cardio-Oncology: Digital Twins and AI for Personalized Cardiovascular Risk Assessment

Dr. Pooja Singh[1], Dr. Arjun Malhotra[2], Mrs. Kavya Rao[3], Dr. Deepak Mishra[4], Mr. Harish Kumar[5]

[1]Professor Department of Pharmaceutics, Western Health Sciences University, Pune, India drpoojasingh.research@gmail.com
[2]Assistant Professor Department of Pharmaceutical Analysis, Western Health Sciences University, Pune, India arjunmalhotra.phd@gmail.com
[3]Professor Department of Pharmacy Practice, Western Health Sciences University, Pune, India kavyarao.academic@gmail.com
[4]Associate Professor Department of Pharmacognosy, Western Health Sciences University, Pune, India deepakmishra.lab@gmail.com
[5]Associate Professor Department of Pharmacology, Western Health Sciences University, Pune, India harishkumar.pharm@gmail.com

ABSTRACT

Background:
Cardio-oncology has emerged as a rapidly evolving multidisciplinary specialty focused on preventing, detecting, and managing cardiovascular complications associated with cancer and its treatment. Although remarkable advances in chemotherapy, targeted therapies, immunotherapy, and radiation therapy have significantly improved cancer survival, cardiovascular disease has become one of the leading causes of long-term morbidity and mortality among cancer survivors. The complex interactions among tumor biology, cardiovascular physiology, therapeutic exposure, genetic susceptibility, immune responses, and patient-specific clinical factors necessitate individualized approaches to cardiovascular risk assessment and management. Recent developments in artificial intelligence (AI), digital twin technology, multimodal data integration, and computational medicine have introduced transformative opportunities for precision cardio-oncology. Digital twins are continuously evolving virtual representations of individual patients that integrate cardiac imaging, electrocardiography, genomic sequencing, laboratory biomarkers, wearable devices, electronic health records, cancer treatment history, and longitudinal clinical information to simulate cardiovascular health, predict treatment-related toxicity, and optimize personalized therapeutic strategies. Advances in machine learning, deep learning, transformer architectures, graph neural networks, reinforcement learning, and explainable artificial intelligence have significantly enhanced cardiovascular prediction, early diagnosis, treatment optimization, and survivorship management. Despite remarkable progress, challenges remain regarding data interoperability, computational complexity, ethical governance, cybersecurity, regulatory validation, and large-scale clinical implementation. This review provides a comprehensive overview of artificial intelligence and digital twin technologies in precision cardio-oncology, highlighting computational foundations, clinical applications, emerging innovations, and future perspectives for personalized cardiovascular risk assessment in patients with cancer.[1]

Keywords: *Cardio-oncology, Artificial intelligence, Digital twins, Precision medicine, Cardiovascular toxicity, Machine learning, Personalized healthcare, Echocardiography, Cardiac imaging, Clinical decision support.*

Article Info
Received: 05 April 2026, received in revised form: 15 April 2026, accepted: 20 April 2026, available online: 30 April 2026; Volume: 2; Issue: 4; Pages: 20-29.

Citation: Singh P., 2026. Precision Cardio-Oncology: Digital Twins and AI for Personalized Cardiovascular Risk Assessment. *International Journal of Multidisciplinary Research in Biotechnology, Pharmacy, Dental and Medical Sciences (IJMRBPDMS)* 2(4): 20-29.
DOI:

Introduction

Advances in modern oncology have dramatically improved survival among patients with cancer, resulting in a rapidly growing population of long-term cancer survivors. However, cardiovascular disease has emerged as one of the most significant non-cancer causes of morbidity and mortality among these individuals. Chemotherapy, targeted therapies, immune checkpoint inhibitors, radiation therapy, hormonal therapies, and hematopoietic stem cell transplantation may produce acute and chronic cardiovascular complications including heart failure, cardiomyopathy, arrhythmias, hypertension, coronary artery disease, myocarditis, thromboembolism, and vascular dysfunction.[2]

The cardiovascular consequences of cancer therapy are highly heterogeneous and influenced by numerous interacting factors including patient age, pre-existing cardiovascular disease, genetic susceptibility, lifestyle characteristics, cancer subtype, treatment intensity, cumulative drug exposure, inflammatory responses, and metabolic alterations. Consequently, conventional population-based cardiovascular risk prediction models frequently fail to accurately estimate individualized risk among patients undergoing cancer treatment.[3]

Modern cardio-oncology increasingly relies upon multimodal biomedical information generated through echocardiography, cardiac magnetic resonance imaging, computed tomography, electrocardiography, laboratory biomarkers, genomic sequencing, wearable physiological monitoring, electronic health records, and longitudinal treatment documentation. Integrating these heterogeneous datasets into personalized clinical decision-making exceeds the analytical capabilities of traditional statistical approaches and routine clinical workflows.[4]

Artificial intelligence has emerged as one of the most transformative technologies supporting precision cardio-oncology. Machine learning algorithms identify complex relationships among cardiovascular variables, deep learning models analyze cardiac imaging, transformer architectures process clinical documentation, and multimodal learning integrates diverse biomedical information into unified computational representations capable of supporting individualized cardiovascular care.[5]

Digital twins further extend these capabilities by creating continuously evolving virtual representations of patients that simulate cardiovascular physiology, disease progression, treatment-related toxicity, and therapeutic response throughout the entire cancer care continuum. These adaptive computational models represent a major step toward predictive, preventive, and personalized cardio-oncology.[6]

2. Evolution of Precision Cardio-Oncology

Cardio-oncology has evolved rapidly over the past two decades in response to increasing recognition of cardiovascular complications associated with modern cancer therapy. Early clinical management primarily focused on detection of symptomatic cardiotoxicity following chemotherapy or radiation therapy. However, growing numbers of long-term cancer survivors highlighted the need for proactive cardiovascular surveillance and preventive interventions.[7]

The introduction of high-sensitivity cardiac biomarkers, advanced echocardiography, cardiac magnetic resonance imaging, molecular cardiology, and genomic medicine substantially improved understanding of treatment-related cardiovascular injury. Simultaneously, electronic health records and digital health technologies generated unprecedented quantities of longitudinal cardiovascular information suitable for computational analysis.[8]

Artificial intelligence accelerated precision cardio-oncology by enabling automated integration of cardiac imaging, electrocardiography, laboratory biomarkers, genomics, treatment history, and clinical outcomes into predictive computational models. Machine learning algorithms demonstrated considerable success in predicting chemotherapy-induced cardiotoxicity, heart failure, arrhythmias, and mortality while supporting individualized cardiovascular risk assessment.[9]

More recently, digital twin technology has expanded computational modeling beyond isolated predictive algorithms toward continuously evolving patient-specific virtual models capable of simulating cardiovascular physiology and therapeutic response throughout cancer diagnosis, treatment, survivorship, and long-term follow-up.[10]

Today, precision cardio-oncology integrates artificial intelligence, multimodal learning, computational cardiology, and digital twins into intelligent healthcare ecosystems capable of supporting personalized cardiovascular management for every patient with cancer.[11]

3. Core Architecture of Cardio-Oncology Digital Twins

A cardio-oncology digital twin consists of multiple interconnected computational layers that continuously exchange information to maintain an adaptive virtual representation of an individual's cardiovascular health throughout the cancer journey. Rather than functioning as a single artificial intelligence algorithm, these systems integrate multiple computational models operating across physiological, molecular, anatomical, and clinical domains.[12]

The first layer involves comprehensive acquisition of patient-specific biomedical information from diverse clinical sources including echocardiography, cardiac magnetic resonance imaging, computed tomography, electrocardiography, laboratory biomarkers such as troponin and natriuretic peptides, genomic sequencing, physiological monitoring, wearable biosensors, cancer treatment history, medication records, and electronic health records.[13]

The second layer performs multimodal data harmonization through standardized preprocessing, feature extraction, quality control, semantic mapping, and interoperability frameworks. Artificial intelligence extracts quantitative imaging biomarkers, processes clinical narratives using natural language processing, encodes genomic information, and integrates longitudinal physiological measurements into unified computational representations.[14]

The third layer incorporates advanced artificial intelligence algorithms responsible for predictive learning. Deep neural networks analyze cardiac imaging, transformer architectures process clinical documentation, graph neural networks represent molecular signaling pathways, and probabilistic models estimate cardiovascular disease progression and treatment-related toxicity. These computational approaches collectively generate individualized patient representations supporting downstream clinical decision-making.[15]

Simulation engines further model cardiac physiology, myocardial remodeling, vascular function, chemotherapy-induced injury, inflammatory responses, arrhythmogenesis, and long-term cardiovascular adaptation. Continuous incorporation of newly acquired patient information enables dynamic prediction of cardiovascular outcomes and optimization of preventive interventions.[16]

The final layer provides interactive clinical dashboards displaying individualized cardiovascular risk estimates, treatment-related toxicity predictions, disease progression simulations, therapeutic recommendations, and evidence-based preventive strategies while maintaining physician oversight throughout the clinical workflow.[17]

4. Artificial Intelligence Technologies Powering Precision Cardio-Oncology

Artificial intelligence serves as the computational foundation of precision cardio-oncology by transforming heterogeneous cardiovascular and oncological information into clinically actionable knowledge. Multiple complementary artificial intelligence methodologies collectively support diagnosis, prognostic prediction, treatment optimization, and long-term cardiovascular surveillance.[18]

Traditional machine learning algorithms including logistic regression, support vector machines, decision trees, random forests, and gradient boosting models initially demonstrated substantial success in predicting chemotherapy-induced cardiotoxicity, cardiovascular mortality, heart failure, arrhythmias, and hospitalization using structured clinical datasets. Although highly effective, these models often required manually engineered features and limited biological representation.[19]

Deep learning significantly expanded predictive capabilities by automatically extracting hierarchical features from cardiac imaging, electrocardiography, laboratory biomarkers, physiological monitoring, and longitudinal clinical information. Convolutional neural networks revolutionized analysis of echocardiography and cardiac magnetic resonance imaging, while recurrent neural networks facilitated temporal modeling of cardiovascular physiology.[20]

Transformer architectures have recently become central to precision cardio-oncology because self-attention mechanisms efficiently integrate imaging findings, laboratory biomarkers, genomic sequencing, cancer treatment history, physician documentation, and electronic health records into unified patient representations supporting highly individualized cardiovascular risk prediction.[21]

Foundation models pretrained on large biomedical datasets further enhance scalability through transfer learning, allowing adaptation across diverse cardiovascular diseases and cancer populations while improving robustness and reducing dependence on manually annotated datasets.[22]

5. Multimodal Data Integration in Cardio-Oncology

Precision cardio-oncology depends fundamentally upon integration of diverse biomedical information into comprehensive computational frameworks. Cardiovascular complications of cancer therapy arise through complex interactions among myocardial biology, vascular physiology, immune responses, inflammation, metabolism, genetics, treatment exposure, and environmental influences. Consequently, isolated datasets rarely provide sufficient information for accurate individualized cardiovascular risk assessment.[23]

Cardiac imaging contributes detailed structural and functional information regarding ventricular performance, myocardial deformation, tissue characterization, coronary anatomy, vascular integrity, and cardiac remodeling. Electrocardiography provides continuous assessment of cardiac rhythm, conduction abnormalities, ischemia, and electrophysiological changes. Laboratory investigations including cardiac troponins, B-type natriuretic peptide, inflammatory biomarkers, metabolic markers, and coagulation profiles further characterize cardiovascular status.[24]

Genomic sequencing identifies inherited cardiovascular susceptibility, pharmacogenomic characteristics, and molecular pathways associated with treatment-related cardiotoxicity. Clinical information—including cancer subtype, chemotherapy exposure, radiation dose, medication history, cardiovascular comorbidities, lifestyle factors, physiological monitoring, and longitudinal follow-up—adds essential context for individualized patient management. Artificial intelligence harmonizes these heterogeneous datasets through multimodal representation learning capable of identifying complex biological relationships beyond conventional statistical analysis.[25]

6. Artificial Intelligence in Cardiac Imaging

Cardiac imaging represents one of the most influential applications of artificial intelligence within cardio-oncology. Echocardiography, cardiac magnetic resonance imaging, computed tomography, nuclear cardiology, and hybrid imaging collectively generate extensive diagnostic information regarding cardiac structure, function, perfusion, fibrosis, and myocardial injury.[26]

Deep learning algorithms automatically segment cardiac chambers, quantify ventricular function, estimate myocardial strain, detect regional wall motion abnormalities, identify fibrosis, and characterize treatment-related structural changes with remarkable precision. These computational approaches substantially improve early identification of chemotherapy-induced cardiomyopathy before clinically significant ventricular dysfunction develops.[27]

Radiomics further expands the clinical value of cardiac imaging by extracting quantitative imaging biomarkers describing myocardial texture, tissue heterogeneity, fibrosis, vascular remodeling, and functional adaptation. Integration of imaging biomarkers with laboratory investigations and genomic information enables highly individualized cardiovascular risk prediction and treatment planning.[28]

7. Artificial Intelligence in Electrocardiography and Cardiac Biomarkers

Electrocardiography remains one of the most widely used cardiovascular diagnostic tools in oncology because numerous anticancer therapies may induce arrhythmias, conduction abnormalities, myocardial ischemia, and electrophysiological alterations. Artificial intelligence has significantly enhanced electrocardiographic interpretation through automated rhythm analysis, QT interval assessment, arrhythmia detection, and prediction of subclinical cardiovascular disease.[29]

Machine learning algorithms integrate electrocardiographic signals with cardiac biomarkers such as troponin, natriuretic peptides, inflammatory markers, and metabolic profiles to improve early detection of cardiotoxicity, myocardial injury, and heart failure. Continuous physiological monitoring through wearable electrocardiographic devices further enables real-time assessment of cardiovascular status during cancer treatment.[30]

Artificial intelligence-driven integration of electrocardiography, laboratory biomarkers, imaging findings, genomic susceptibility, and treatment history supports proactive cardiovascular surveillance, individualized preventive strategies, and adaptive clinical decision-making throughout the cancer care continuum.[31]

8. Artificial Intelligence for Early Detection of Cancer Therapy–Related Cardiotoxicity

Cancer therapy–related cardiotoxicity remains one of the greatest challenges in cardio-oncology because myocardial injury frequently develops before clinical symptoms become apparent. Early identification of subclinical cardiac dysfunction is therefore essential for preventing irreversible cardiovascular damage while allowing continuation of potentially life-saving anticancer therapy. Artificial intelligence significantly enhances early detection by integrating multimodal cardiovascular information into predictive computational models capable of identifying patients at highest risk for treatment-related cardiac complications.[32]

Machine learning algorithms analyze echocardiographic strain imaging, cardiac magnetic resonance imaging, electrocardiographic signals, serum biomarkers, genomic information, physiological monitoring, cumulative chemotherapy exposure, and clinical characteristics to estimate individualized cardiotoxicity risk. These predictive models enable clinicians to initiate cardioprotective interventions before significant ventricular dysfunction develops, thereby improving long-term cardiovascular outcomes.[33]

9. Precision Risk Stratification Using Artificial Intelligence

Traditional cardiovascular risk prediction models often underestimate the complexity of patients receiving cancer treatment because they generally do not incorporate oncology-specific variables. Artificial intelligence overcomes this limitation by integrating cancer subtype, treatment regimen, cumulative drug dose, radiation exposure, cardiovascular comorbidities, genetic susceptibility, laboratory biomarkers, cardiac imaging, and physiological monitoring into comprehensive predictive models.

These computational systems estimate individualized probabilities of heart failure, arrhythmias, myocardial infarction, hypertension, thromboembolic events, myocarditis, pericardial disease, and cardiovascular mortality throughout the patient's cancer journey. Dynamic updating of risk estimates as new clinical information becomes available allows continuous refinement of personalized preventive strategies and therapeutic recommendations.[34]

Artificial intelligence also supports individualized follow-up schedules by identifying patients requiring intensive cardiovascular surveillance while minimizing unnecessary investigations among lower-risk individuals, thereby improving healthcare efficiency and resource utilization.[35]

10. Artificial Intelligence in Personalized Therapeutic Planning

Personalized therapeutic planning represents one of the greatest clinical advantages of precision cardio-oncology. Artificial intelligence enables clinicians to evaluate multiple treatment strategies while simultaneously considering oncological efficacy and cardiovascular safety. Rather than relying exclusively on standardized treatment protocols, patient-specific computational models estimate individualized benefit-risk profiles according to each patient's cardiovascular condition and cancer characteristics.

Machine learning algorithms predict response to chemotherapy, targeted therapy, immunotherapy, radiation therapy, and cardioprotective medications while estimating treatment-related cardiovascular toxicity, progression-free survival, and overall survival. These predictive simulations support individualized selection of cancer therapies, cardiovascular medications, treatment sequencing, and supportive interventions while minimizing adverse outcomes.[36]

Continuous incorporation of updated imaging findings, laboratory investigations, physiological monitoring, and treatment response enables adaptive therapeutic optimization throughout cancer treatment and survivorship, recognizing that both cardiovascular physiology and cancer biology evolve continuously over time.[37]

11. Artificial Intelligence in Cardiac Rehabilitation and Survivorship

The rapidly expanding population of cancer survivors has increased demand for comprehensive cardiovascular rehabilitation and long-term survivorship care. Many survivors experience persistent cardiovascular complications including heart failure, hypertension, arrhythmias, coronary artery disease, metabolic dysfunction, reduced exercise capacity, and diminished quality of life.

Artificial intelligence supports personalized rehabilitation by integrating treatment history, cardiac imaging, exercise capacity, physiological monitoring, laboratory biomarkers, wearable technologies, medication adherence, nutritional status, and lifestyle factors into individualized rehabilitation programs. Machine learning algorithms estimate recovery trajectories while recommending optimized exercise prescriptions, cardiovascular monitoring schedules, and preventive interventions according to patient-specific characteristics.[38]

Continuous remote monitoring further enables clinicians to evaluate rehabilitation progress, identify early deterioration, improve medication adherence, and support long-term cardiovascular health after completion of cancer therapy.[39]

12. Artificial Intelligence in Drug Discovery and Cardio-Protective Therapeutics

Development of effective cardioprotective therapies remains a major priority in cardio-oncology. Artificial intelligence accelerates drug discovery by integrating molecular cardiology, pharmacology, genomics, systems biology, and clinical data into computational models capable of predicting therapeutic efficacy and safety before laboratory or clinical testing.

Machine learning algorithms identify molecular targets associated with chemotherapy-induced myocardial injury, oxidative stress, mitochondrial dysfunction, inflammation, fibrosis, endothelial injury, and vascular remodeling. Computational simulations further predict pharmacokinetic and pharmacodynamic properties, optimize dosing strategies, and estimate cardiovascular toxicity of newly developed anticancer agents.[40]

Artificial intelligence also supports design of adaptive clinical trials by identifying patients most likely to benefit from investigational cardioprotective therapies, improving participant stratification, reducing trial variability, and accelerating regulatory approval of innovative cardiovascular interventions for oncology patients.[41]

13. Explainable Artificial Intelligence and Trustworthy Cardio-Oncology

Successful clinical implementation of artificial intelligence requires transparency and interpretability so that clinicians can understand the rationale underlying computational recommendations. Explainable artificial intelligence (XAI) addresses this requirement by providing clinically meaningful explanations rather than functioning as opaque "black-box" prediction systems.

Saliency maps identify cardiac imaging regions contributing most strongly to diagnostic predictions, while SHAP (Shapley Additive Explanations) values quantify the influence of laboratory biomarkers, imaging findings, treatment variables, physiological measurements, genomic alterations, and cardiovascular risk factors on individualized prediction models. Counterfactual explanations further demonstrate how modifications in treatment strategies or patient characteristics may alter predicted cardiovascular outcomes.[42]

Explainable artificial intelligence improves communication among cardiologists, oncologists, radiologists, pharmacists, nurses, rehabilitation specialists, and patients while strengthening clinician confidence, reducing algorithmic bias, supporting regulatory approval, and promoting responsible implementation of precision cardio-oncology technologies.[43]

14. Federated Learning, Cybersecurity, and Ethical Considerations

Large-scale precision cardio-oncology requires collaboration among cancer centers, cardiovascular institutes, imaging laboratories, genomic facilities, and international research networks. However, direct sharing of sensitive patient information raises substantial concerns regarding privacy, confidentiality, cybersecurity, and ethical governance.

Federated learning enables collaborative development of artificial intelligence models without transferring raw patient data between participating institutions. Each hospital trains algorithms locally using its own cardiovascular and oncology datasets, while only encrypted model parameters are securely aggregated into improved global models. This decentralized learning strategy preserves patient privacy while enabling continuous learning across geographically diverse healthcare systems.[44]

Additional privacy-preserving technologies—including differential privacy, secure multi-party computation, homomorphic encryption, blockchain-based audit systems, and encrypted cloud computing—further strengthen cybersecurity within cardio-oncology ecosystems. Robust authentication protocols, encrypted communication channels, identity management systems, intrusion detection technologies, and continuous threat monitoring remain essential because artificial intelligence platforms continuously exchange highly sensitive cardiovascular and oncological information across interconnected healthcare infrastructures.[45]

15. Digital Biomarkers and Continuous Cardiovascular Monitoring

The rapid expansion of wearable technologies, implantable cardiac devices, mobile health applications, and remote physiological monitoring has significantly enhanced precision cardio-oncology. Unlike conventional cardiovascular surveillance based on periodic hospital visits, continuous monitoring enables real-time assessment of cardiac physiology throughout cancer treatment and survivorship. Digital biomarkers derived from heart rate, heart rate variability, electrocardiographic signals, blood pressure, oxygen saturation, physical activity, sleep quality, respiratory rate, and patient-reported symptoms provide valuable insights into cardiovascular health and treatment tolerance.[46]

Artificial intelligence continuously integrates these physiological measurements with cardiac imaging, laboratory biomarkers, medication history, cancer treatment exposure, and electronic health records to identify early signs of myocardial injury, arrhythmias, heart failure, hypertension, thromboembolic events, and autonomic dysfunction before clinically significant deterioration occurs. Early recognition enables prompt intervention, reducing hospitalization, improving treatment continuity, and enhancing long-term cardiovascular outcomes.

Continuous monitoring further supports patient-centered survivorship by allowing clinicians to personalize follow-up schedules according to individualized cardiovascular risk rather than standardized surveillance protocols. Integration of wearable technologies with intelligent clinical decision-support systems extends cardiovascular care beyond traditional hospital settings while improving accessibility and quality of life.[47]

16. Artificial Intelligence in Long-Term Cancer Survivorship

As survival after cancer continues to improve, long-term cardiovascular health has become a central component of survivorship care. Many cancer survivors experience chronic cardiovascular complications resulting from chemotherapy, radiation therapy, targeted therapies, endocrine therapy, or immunotherapy. These complications may develop years after completion of treatment and substantially affect quality of life and long-term survival.

Artificial intelligence supports personalized survivorship by integrating treatment history, cumulative drug exposure, radiation dose, genomic susceptibility, cardiac imaging, laboratory biomarkers, lifestyle factors, physiological monitoring, and longitudinal clinical information into predictive computational models. Machine learning algorithms estimate individualized risks of heart failure, coronary artery disease, arrhythmias, hypertension, valvular disease, vascular dysfunction, and secondary cardiovascular events while recommending personalized surveillance strategies and preventive interventions.[48]

Such individualized follow-up improves early identification of late cardiovascular toxicity, facilitates timely cardioprotective therapy, and reduces unnecessary investigations among lower-risk survivors, thereby optimizing long-term healthcare delivery.

17. Emerging Innovations in Artificial Intelligence and Digital Twins

Rapid advances in computational medicine continue to expand the capabilities of artificial intelligence and digital twins within precision cardio-oncology. Foundation models trained on multimodal biomedical datasets are expected to improve prediction accuracy across diverse cardiovascular diseases and cancer populations while requiring substantially less task-specific retraining.

Generative artificial intelligence has demonstrated considerable potential for biomarker discovery, therapeutic target identification, molecular design, synthetic biomedical data generation, automated clinical documentation, and scientific hypothesis generation. Reinforcement learning algorithms further optimize adaptive cardiovascular management by continuously learning from patient outcomes and refining preventive and therapeutic recommendations throughout the cancer journey.[49]

Graph neural networks increasingly model complex biological interactions among genes, proteins, inflammatory pathways, myocardial remodeling, vascular biology, immune responses, and treatment-related molecular mechanisms. These computational approaches provide deeper insights into cardiovascular toxicity while facilitating development of individualized therapeutic strategies.[50]

18. Integrated Cardio-Oncology Ecosystems

Future cardio-oncology will increasingly operate within intelligent healthcare ecosystems integrating cardiology, oncology, radiology, pathology, genomics, laboratory medicine, pharmacy, rehabilitation, wearable technologies, telemedicine, and electronic health records into unified computational platforms.

Artificial intelligence serves as the computational foundation connecting these diverse healthcare components through continuous multimodal learning and real-time clinical decision support. Such integrated ecosystems facilitate seamless communication among cardiologists, oncologists, radiologists, pharmacists, nurses, rehabilitation specialists, and primary care physicians while improving treatment coordination, medication safety, cardiovascular surveillance, and survivorship care.[51]

Cloud computing, edge computing, Internet of Medical Things (IoMT), blockchain technology, secure interoperability standards, and high-performance computational infrastructure are expected to further improve scalability, computational efficiency, accessibility, and secure exchange of biomedical information across future cardio-oncology networks.[52]

19. Future Perspectives

The future of precision cardio-oncology is increasingly centered on individualized computational medicine capable of continuously integrating cardiovascular imaging, electrocardiography, laboratory biomarkers, genomics, physiological monitoring, wearable technologies, cancer treatment history, and longitudinal clinical information into adaptive patient-specific healthcare systems.

Future research should prioritize large multicenter prospective studies evaluating real-world implementation of artificial intelligence and digital twins across diverse cancer populations and healthcare systems. Standardization of imaging protocols, biomarker assessment, computational validation, interoperability frameworks, explainability methodologies, and regulatory pathways will be essential for widespread clinical adoption.[53]

International collaboration among cardiologists, oncologists, radiologists, biomedical engineers, computer scientists, molecular biologists, regulatory agencies, and healthcare organizations will accelerate development of trustworthy, scalable, and equitable precision cardio-oncology platforms capable of supporting routine clinical practice worldwide.[54]

20. Discussion

Artificial intelligence and digital twin technology represent one of the most significant advances in precision cardio-oncology by enabling comprehensive integration of cardiac imaging, electrocardiography, laboratory biomarkers, genomics, physiological monitoring, wearable technologies, cancer treatment history, and longitudinal clinical information into unified computational frameworks.

Applications including cardiotoxicity prediction, individualized cardiovascular risk assessment, therapeutic optimization, rehabilitation, remote monitoring, survivorship care, and multidisciplinary clinical decision support demonstrate the broad clinical utility of these technologies. Rather than replacing clinicians, artificial intelligence functions as an intelligent clinical partner that enhances evidence-based decision-making while preserving physician expertise and patient-centered care.[55]

Despite remarkable progress, important challenges remain before widespread implementation becomes feasible. Data heterogeneity, interoperability limitations, algorithmic bias, computational complexity, cybersecurity concerns, ethical governance, regulatory approval, healthcare disparities, and clinician acceptance continue to represent major barriers. Addressing these challenges will require multidisciplinary collaboration, rigorous prospective validation, transparent governance, and internationally harmonized standards to ensure safe and responsible implementation of artificial intelligence in cardio-oncology.[56]

21. Conclusion

Artificial intelligence and digital twins are transforming precision cardio-oncology by enabling comprehensive integration of multimodal cardiovascular and oncological information into individualized clinical decision-making. Through advanced analysis of cardiac imaging, electrocardiography, laboratory biomarkers, genomics, wearable technologies, electronic health records, and cancer treatment history, these intelligent systems support personalized cardiovascular risk assessment, early detection of cardiotoxicity, treatment optimization, rehabilitation, and long-term survivorship care.[57]

Continued advances in foundation models, explainable artificial intelligence, federated learning, multimodal learning, graph neural networks, reinforcement learning, and digital twin technology are expected to further improve diagnostic accuracy, computational efficiency, interpretability, scalability, and accessibility across cardio-oncology.[58]

Although significant scientific, technical, ethical, and regulatory challenges remain, ongoing interdisciplinary research continues to accelerate translation of artificial intelligence into routine cardiovascular care for patients with cancer. By enabling predictive analytics, adaptive monitoring, personalized prevention, and individualized therapeutic planning, these technologies have the potential to reduce cardiovascular morbidity, improve cancer survivorship, and establish the foundation for the next generation of precision cardio-oncology worldwide.[59]

Future integration of artificial intelligence, digital twins, digital biomarkers, remote monitoring, precision therapeutics, and collaborative international research networks is expected to transform cardio-oncology into a continuously learning healthcare ecosystem capable of delivering safer, more effective, and truly personalized cardiovascular care for every patient undergoing cancer treatment.[60]

References

1. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
2. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.
3. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.
4. Kumar RMH. Childhood-Oncology Intelligence for Predicting Cancer Emergence, Optimizing Precision Therapies, and Simulating Lifelong Outcomes in Pediatric Malignancies Using Autonomous Foundation Models. Int J Drug Deliv Technol.2026;16(65s):162-173.DOI:10.25258/ijddt.16.65s.19
5. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881-4.
6. Rajendran LKK. Hematological Malignancy Identification via K-means based ROI Extraction. International Journal of Clinical Research in Medical Sciences. 2026;1(2):1-10. Doi:10.67231/kt1w3e73.
7. Maradi Hemanth Kumar R. Dynamic Digital Twins in Oncology: Foundation AI Models for Real-Time Predictive and Personalized Cancer Care. Power System Protection and Control. 2025;53(4):549-563. Doi:10.46121/pspc.53.4.38.
8. Kumar RMH. Pan-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models. Power System Protection and Control. 2023;51(4):92-100. Doi:10.46121/pspc.51.4.8.
9. Rajendran LKK. Identifying Determinants of Outcome in Post-Radiotherapy Cervical Carcinoma Requiring Adjuvant Surgery. International Journal of Clinical Research in Medical Sciences. 2026;1(2):1-10. Doi:10.67231/3acej759.
10. Maradi Hemanth Kumar R. AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology. Power System Protection and Control. 2023;51(4):66-83. Doi:10.46121/pspc.51.4.7.
11. Rajendran LKK. Machine Learning–Driven Symptom-Based Cancer Risk Stratification:A Systematic Review of Clinical Prediction Models and Methodological Rigor. Int J Drug Deliv Technol. 2026;16(40s):242-253.Doi:10.25258/ijddt.16.40s.26.
12. Kumar RMH. Maternal–Fetal Oncology Intelligence: Self-Evolving Foundation Models and Digital Twin Ecosystems for Precision Cancer Prediction, Treatment Optimization, and Maternal–Fetal Outcome Forecasting. Int J Drug Deliv Technol. 2026;16(65s):174-185. DOI: 10.25258/ijddt.16.65s.20
13. Rajendran OK. Bias, Fairness, and Ethical Challenges in Artificial Intelligence: A Comprehensive Review of Causes, Impacts, and Mitigation Strategies. Scientific Culture. 2026;12(2.1):13001-13010. Doi:10.5281/zenodo.20374091.
14. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56. Doi:10.1038/s41591-018-0300-7.
15. Kumar RMH. Precision Oncofertility: Integrating Genomics, Reproductive Biomarkers, Treatment Toxicity Profiles, and Foundation Models for Fertility Preservation in Men and Women with Cancer. Int J Drug Deliv Technol. 2026;16(65s):186-200. DOI: 10.25258/ijddt.16.65s.21
16. Rajendran OK. Clinical Translation of Artificial Intelligence in Oncology: Real-World Validation, Workflow Integration, and Precision Medicine Applications. Int J Drug Deliv Technol. 2026;16(49s):956-964. Doi:10.25258/ijddt.16.49s.110.
17. Rajendran LKK. Interpretable Machine Learning for Early Mortality Prediction in Acute Myeloid Leukemia: A Decision Tree–Based Retrospective Cohort Study. Int J Drug Deliv Technol. 2026;16(40s):231-241.Doi:10.25258/ijddt.16.40s.25.
18. Kumar RMH. Self-Evolving Digital Twin Ecosystems for Early Detection and Precision Management of Breast, Lung, Colorectal, and Ovarian Cancers. Int J Drug Deliv Technol. 2026;16(65s):201-212. DOI: 10.25258/ijddt.16.65s.22
19. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24–29. Doi:10.1038/s41591-018-0316-z.
20. Rajendran OK. Generative AI for Synthetic Medical Image Generation in Oncology: Addressing Data Scarcity in AI-Driven Cancer Diagnosis. Int J Drug Deliv Technol. 2026;16(49s):1010-1016. Doi:10.25258/ijddt.16.49s.117.
21. Rajendran LKK. Integrated Prognostic Modeling of Tumor Stage, Multimodal Therapy, and Functional Status in Lung Cancer Survival: A Real-World Cohort Study. Scientific Culture. 2026;12(5):567-576. Doi: 10.5281/zenodo.20738481.

22. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.
23. Rajendran LKK. Integrative Pharmacogenomic Analysis of Drug Response Heterogeneity Across Cancer Cell Lines: Insights From Large-Scale GDSC Data. Scientific Culture. 2026;12(4):7537-7546. Doi:10.5281/zenodo.20767386.
24. Acs B, Rantalainen M, Hartman J. Artificial intelligence as the next step towards precision pathology. J Intern Med. 2020;288(1):62–81. Doi:10.1111/joim.13030.
25. Rajendran OK. Tumor Microenvironment Interaction-Guided Graph Neural Networks for Survival Prediction from Whole-Slide Pathology Images. Int J Drug Deliv Technol. 2026;16(49s):481-488. Doi:10.25258/ijddt.16.49s.50.
26. Rajendran LKK. Evaluating the Association of Cancer-Related Risk Factors With Multisystem Health: Insights Into Fertility, Cardiovascular, and Renal Indicators. Scientific Culture. 2026;12(4):7520-7527.Doi:10.5281/zenodo.20767374.
27. Rajendran LKK. From Prediction to Precision: An Externally Validated Deep Learning–Based Survival and Adjuvant Therapy Recommendation System for Resected Stage III Non–Small Cell Lung Cancer. Int J Drug Deliv Technol. 2026;16(30s):430-438.doi:10.25258/ijddt.16.30s.41.
28. Kumar RMH. Multimodal foundation AI models in precision oncology: Integrating radiomics, pathomics, multi-omics, and clinical intelligence systems. Power System Protection and Control. 2024;52(4):189-204. Doi:10.46121/pspc.52.4.16.
29. Rajendran LKK. From Prediction to Practice: A Machine Learning–Based Clinical Decision Support Tool for Bevacizumab Risk Stratification in Oncology. Int J Drug Deliv Technol. 2026;16(30s):414-429. Doi:10.25258/ijddt.16.30s.40.
30. Rajendran OK. Self-supervised multimodal Learning for early cancer detection across Imaging and genomics. Power System Protection and Control. 2024;52(4):167-178. Doi:10.46121/pspc.52.4.14.
31. Rajendran OK. Explainable AI-Driven Clinical. Decision Support Systems in Precision Oncology:Interpretable Models for Multimodal Cancer Care. Scientific Culture. 2026;12(2.1):12359-12369. Doi:10.5281/zenodo.20328194.
32. Rajendran LKK. Impact of Treatment Modalities on Fertility, Sexual Function, and Psychological Outcomes in Testicular Cancer Survivors: A Comprehensive Review. Int J Drug Deliv Technol. 2026;16(30s):447-453. Doi:10.25258/ijddt.16.30s.43.
33. Rajendran LKK. Intelligent Omics-Driven Patient Stratification for Cancer Therapeutic Re-profiling. International Journal of Clinical Research in Medical Sciences. 2026;1(1):1-11. Doi:10.67231/gvshck05.
34. Rajendran LKK. Cancer nanomedicine: utilizing the enhanced permeability and retention (EPR) effect to deliver high payloads of chemotherapeutic agents directly to tumor sites. Power System Protection and Control. 2024;52(2):123-129. Doi:10.46121/pspc.52.2.12.
35. Kather JN, Calderaro J. Development of AI in digital pathology. Nat Rev Clin Oncol. 2020;17(10):591–595. Doi:10.1038/s41571-020-00431-0.
36. Rajendran OK. AI-based radiogenomic Models for predicting immunotherapy response In solid tumors. Power System Protection and Control. 2023;51(4):24-37. Doi:10.46121/pspc.51.4.4.
37. Rajendran LKK. Enhanced Predictive Analytics for Early Malignancy Discovery in Routine Screening. International Journal of Clinical Research in Medical Sciences. 2026;1(1):1-10. Doi:10.67231/grams870.
38. Rajendran OK. Machine Learning-Based Prediction of Chemotherapy Toxicity in Colorectal Cancer: A Personalized Risk Stratification Approach. Scientific Culture. 2026;12(5.1):942-952. Doi:10.5281/zenodo.20767359.
39. Rajendran OK. Federated radiology AI Models for multi-institutional cancer diagnosis Without data sharing. Power System Protection And Control. 2023;51(4):38-54. Doi:10.46121/pspc.51.4.5.
40. Kumar RMH. AI-augmented immuno-oncology: Foundation models for predicting immune response, resistance, and precision immunotherapy. Power System Protection and Control. 2024;52(2):193-208. Doi:10.46121/pspc.52.2.18.
41. Rajendran OK. Deep Reinforcement Learning in Oncology: Advances in Cancer Imaging, Radiotherapy, and Personalized Treatment. Scientific Culture. 2026;12(5):597-606. Doi:10.5281/zenodo.20767337.
42. Rajendran OK. DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING. Power System Protection and Control. 2025;53(3):313-328. Doi:10.46121/pspc.53.3.21.
43. Lu MY, Chen TY, Williamson DFK, et al. AI-based pathology predicts origins for cancers of unknown primary. Nature. 2021;594(7861):106–110. Doi:10.1038/s41586-021-03512-4.
44. Rajendran OK. Artificial Intelligence in Oncologic Imaging: Deep Learning, Radiomics, and Clinical Integration for Precision Cancer Diagnosis. Int J Drug Deliv Technol. 2026;16(50s):871-880. Doi:10.25258/ijddt.16.50s.92.

45. Bilal M, Raza SEA, Azam A, et al. Development and validation of a weakly supervised deep learning framework to predict the risk of colorectal cancer recurrence from histology images. Lancet Oncol. 2021;22(11):153–163. Doi:10.1016/S1470-2045(21)00430-5.
46. Rajendran OK. DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA. Power System Protection and Control. 2025;53(4):486-501. Doi:10.46121/pspc.53.4.33.
47. Rajendran LKK. Genomic profiling: utilizing Multi-omics data to identify potential Therapeutic targets and resistance markers. Power System Protection and Control. 2024;52(4):159-166. Doi:10.46121/pspc.52.4.13.
48. Rajendran OK. Artificial Intelligence–Driven Multimodal Imaging for Cancer During Pregnancy: Advances in Maternal–Fetal Diagnostics and Precision Oncology. Int J Drug Deliv Technol. 2026;16(50s):862-870. Doi:10.25258/ijddt.16.50s.91.
49. Rajendran LKK. Immunotherapy and cell Therapy: developing CAR-T cell therapies and Other immune-based treatments for cancer and Autoimmune diseases. Power System Protection and Control. 2023;51(2):64-77. Doi:10.46121/pspc.51.2.7.
50. Rajendran OK. FOUNDATION MODEL–DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE. Power System Protection and Control. 2024;52(2):154-163. Doi:10.46121/pspc.52.2.14.
51. Rajendran LKK. Theranostics: integrating Diagnostic imaging agents and therapeutic Drugs into a single multifunctional nano-Platform for real-time monitoring of treatment. Power System Protection and Control.2025;53(2):376-386. Doi:10.46121/pspc.53.2.31.
52. Rajendran LKK. Mechanisms driving Immunotherapy resistance in colorectal cancer Liver metastases. Power System Protection and Control. 2024;52(1):29-37. Doi:10.46121/pspc.52.1.5.
53. Ching T, Himmelstein DS, Beaulieu-Jones BK, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15(141):20170387. Doi:10.1098/rsif.2017.0387.
54. Litjens G, Kooi T, Bejnordi BE, et al. A survey on deep learning in medical image analysis. Med Image Anal. 2017;42:60–88. Doi:10.1016/j.media.2017.07.005.
55. Hemanth Kumar RM. Integrated Transcriptomic and 3 Learning Framework Identifies a Blood-Based Biomarker Signature for Anthracycline-Induced Cardiotoxicity in Juvenile Cancer Survivors. Int J Drug Deliv Technol. 2026;16(40s):219-230. Doi:10.25258/ijddt.16.40s.24.
56. Mobadersany P, Yousefi S, Amgad M, et al. Predicting cancer outcomes from histology and genomics using convolutional networks. Proc Natl Acad Sci USA. 2018;115(13):E2970–E2979. Doi:10.1073/pnas.1717139115.
57. Rajendran OK. DeepDRA: A Deep Learning Framework for Drug Repurposing and Cancer Drug Response Prediction Using Multi-Omics Data. Scientific Culture. 2026;12(3):68-77. doi:10.5281/zenodo.20767428.
58. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749–762. Doi:10.1038/nrclinonc.2017.141.
59. Azizi S, Mustafa B, Ryan F, et al. Big self-supervised models advance medical image classification. Nature. 2021;594(7864):104–110. Doi:10.1038/s41586-021-03476-6.
60. Dosovitskiy A, Beyer L, Kolesnikov A, et al. An image is worth 16×16 words: transformers for image recognition at scale. arXiv. 2020. Doi:10.48550/arXiv.2010.11929.